Colistimethate sodium

多黏菌素E甲磺酸钠

Report date: 2026/04/09 20:00:21
NMEQIDP

Base Information

Drug NameColistimethate sodium
Drug Alias NameColistin sulphomethate克痢霉菌Colistimethatum natricum多粘菌素E甲磺酸钠粘菌素钠 +[21] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Lipopeptide antibiotics
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHospital-acquired pneumoniaPseudomonas aeruginosa pneumoniaBronchiectasis +[9] 
Global Approved IndicationsGram-Negative Bacterial Infections
Approved Indications in ChinaGram-Negative Bacterial Infections
Original Approved Country/TerritoryUnited States
Original Approved Date1970/06/04
Country/TerritoryBelgiumCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesPH Health LtdEssential Pharma (M) LtdBeacon Pharmaceuticals Ltd +[8] 
Inactive CompaniesGlaxosmithkline PlcZambon SpaQilu Pharmaceutical(Hainan) Co Ltd +[4] 
Active IndicationsHospital-acquired pneumoniaPseudomonas aeruginosa pneumoniaCystic Fibrosis +[6] 
Inactive IndicationsBronchiectasisHealthcare-Associated PneumoniaPseudomonas Infections

Other Information

ATC CodeA07AA10J01XB01
Related LinksWikipediaDrugBankKEGG